Who are Dapsone 5.0% Gel (SEEGPharm)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dapsone 7.5 % gel, Dapsone 5.0% Gel (Allergan), dapsone gel vehicle.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapsone-5-0-gel-seegpharm.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dapsone 5.0% Gel (SEEGPharm) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dapsone 5.0% Gel (SEEGPharm) (Dapsone 5.0% Gel (SEEGPharm)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfone antibiotic with anti-inflammatory properties. Area: Dermatology.

phase 3 Sulfone antibiotic with anti-inflammatory properties Dihydropteroate synthase (bacterial); neutrophil function and ROS production (host) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Dapsone 5.0% Gel (SEEGPharm) (Dapsone 5.0% Gel (SEEGPharm)) — Seegpharm S.A.. Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties through suppression of neutrophil function and reactive oxygen species production.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dapsone 5.0% Gel (SEEGPharm) TARGET	Dapsone 5.0% Gel (SEEGPharm)	Seegpharm S.A.	phase 3	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase (bacterial); neutrophil function and ROS production (host)
Dapsone 7.5 % gel	Dapsone 7.5 % gel	Derm Research, PLLC	marketed	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase; neutrophil function and inflammatory mediators
Dapsone 5.0% Gel (Allergan)	Dapsone 5.0% Gel (Allergan)	Seegpharm S.A.	phase 3	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase (bacterial); neutrophil function and ROS production (host)
dapsone gel vehicle	dapsone gel vehicle	Almirall, S.A.	phase 3	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase; neutrophil function modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfone antibiotic with anti-inflammatory properties class)

Seegpharm S.A. · 2 drugs in this class
Almirall, S.A. · 1 drug in this class
Derm Research, PLLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dapsone 5.0% Gel (SEEGPharm) — Competitive Intelligence Brief. https://druglandscape.com/ci/dapsone-5-0-gel-seegpharm. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab